ES2272319T3
(es)
|
1999-08-27 |
2007-05-01 |
Chemocentryx, Inc. |
Compuestos heterociclicos y metodos para modular la funcion de cxcr3.
|
US20070021493A1
(en)
|
1999-09-16 |
2007-01-25 |
Curis, Inc. |
Mediators of hedgehog signaling pathways, compositions and uses related thereto
|
US6545004B1
(en)
*
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US8852937B2
(en)
|
2000-03-30 |
2014-10-07 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US7115653B2
(en)
|
2000-03-30 |
2006-10-03 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2002083143A1
(en)
*
|
2000-12-11 |
2002-10-24 |
Tularik Inc. |
Cxcr3 antagonists
|
US6992082B2
(en)
|
2001-01-19 |
2006-01-31 |
Cytokinetics, Inc. |
Phenothiazine kinesin inhibitors
|
US6900214B2
(en)
|
2001-03-29 |
2005-05-31 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6809102B2
(en)
|
2001-03-29 |
2004-10-26 |
Bristol-Myers Squibb Company |
Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
HUP0400264A2
(hu)
|
2001-06-22 |
2004-08-30 |
Pfizer Products Inc. |
Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
|
EP2329822A1
(de)
|
2001-09-05 |
2011-06-08 |
Minerva Biotechnologies Corporation |
Zusammensetzungen und deren Verwendung zur Behandlung von Krebs
|
EP1444209A4
(de)
|
2001-11-07 |
2005-02-16 |
Merck & Co Inc |
Inhibitoren mitotischer kinesine
|
WO2003043961A2
(en)
*
|
2001-11-19 |
2003-05-30 |
Iconix Pharmaceuticals, Inc. |
Modulators of rho c activity
|
WO2003043995A1
(en)
*
|
2001-11-20 |
2003-05-30 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
AU2002363960B2
(en)
*
|
2001-12-06 |
2008-07-10 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
CA2467726A1
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
ES2291543T3
(es)
*
|
2001-12-06 |
2008-03-01 |
MERCK & CO., INC. |
Inhibicion de kinesina mitotica.
|
DE60234278D1
(de)
|
2001-12-06 |
2009-12-17 |
Merck & Co Inc |
Mitotische kinesin-hemmer
|
DE60231439D1
(de)
*
|
2001-12-06 |
2009-04-16 |
Merck & Co Inc |
Mitotische kinesinhemmer
|
EP1454903B9
(de)
|
2001-12-11 |
2011-10-05 |
Kyowa Hakko Kirin Co., Ltd. |
Thiadiazolinderivate zur Krebsbehandlung
|
PL373412A1
(en)
*
|
2002-05-09 |
2005-08-22 |
Cytokinetics, Inc. |
Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases
|
CA2486215A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
DE60326248D1
(de)
*
|
2002-07-17 |
2009-04-02 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
|
AU2003299612A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Cytokinetics |
Compounds, compositions and methods
|
CN1894234A
(zh)
*
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2004092123A2
(en)
*
|
2003-04-10 |
2004-10-28 |
Microbia, Inc. |
Inhibitors of fungal invasion
|
ATE537158T1
(de)
|
2003-04-18 |
2011-12-15 |
Kyowa Hakko Kirin Co Ltd |
M-stage-kinesin-inhibitor
|
CN1809563A
(zh)
|
2003-06-20 |
2006-07-26 |
希龙公司 |
吡啶并[1,2-a]嘧啶-4-酮化合物用作抗癌药
|
US7666862B2
(en)
*
|
2003-08-15 |
2010-02-23 |
Merck & Co., Inc. |
Mitotic Kinesin Inhibitors
|
US7939539B2
(en)
*
|
2003-11-25 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Quinazolinone compounds as anticancer agents
|
US7439254B2
(en)
*
|
2003-12-08 |
2008-10-21 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
US7662581B1
(en)
|
2003-12-18 |
2010-02-16 |
Novartis Vaccines And Diagnostics, Inc. |
Eg5 co-crystals
|
CN1898215A
(zh)
|
2003-12-19 |
2007-01-17 |
默克公司 |
有丝***驱动蛋白抑制剂
|
JPWO2005061707A1
(ja)
*
|
2003-12-24 |
2007-07-12 |
協和醗酵工業株式会社 |
癌細胞のEg5阻害剤に対する感受性を判定する方法
|
CN1934066A
(zh)
*
|
2004-03-22 |
2007-03-21 |
默克公司 |
有丝***驱动蛋白抑制剂
|
EP1737831B1
(de)
|
2004-04-02 |
2013-05-22 |
Prana Biotechnology Limited |
Neurologisch aktive verbindungen
|
EP1761540B1
(de)
*
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta
|
AU2005245492A1
(en)
|
2004-05-21 |
2005-12-01 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted quinoline derivatives as mitotic kinesin inhibitors
|
EP1755609A1
(de)
*
|
2004-05-25 |
2007-02-28 |
Icos Corporation |
Verfahren zur behandlung und/oder prävention von überschiessender proliferation von hämatopoetischen zellen
|
RU2427572C2
(ru)
|
2004-06-18 |
2011-08-27 |
Чирон Корпорейшн |
N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
|
US7939538B2
(en)
|
2004-06-28 |
2011-05-10 |
Amgen Inc. |
Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
|
US7271271B2
(en)
|
2004-06-28 |
2007-09-18 |
Amgen Sf, Llc |
Imidazolo-related compounds, compositions and methods for their use
|
US7375102B2
(en)
|
2004-06-28 |
2008-05-20 |
Amgen Sf, Llc |
Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
|
JP2008509977A
(ja)
|
2004-08-18 |
2008-04-03 |
アストラゼネカ アクチボラグ |
癌の処置及び予防における選択された縮合複素環の鏡像異性体及びその使用
|
JP5635726B2
(ja)
*
|
2004-09-14 |
2014-12-03 |
ミネルバ バイオテクノロジーズ コーポレーション |
癌の診断方法及び治療方法
|
EP2275412A1
(de)
|
2004-10-19 |
2011-01-19 |
Novartis Vaccines and Diagnostics, Inc. |
Indol- und Benzimidazolderivate
|
CN101107253A
(zh)
*
|
2005-01-19 |
2008-01-16 |
默克公司 |
有丝***驱动蛋白抑制剂
|
DE102005011822A1
(de)
*
|
2005-03-15 |
2006-09-21 |
Merck Patent Gmbh |
Phthalazinone
|
WO2006137490A1
(ja)
|
2005-06-24 |
2006-12-28 |
Kyowa Hakko Kogyo Co., Ltd. |
再狭窄治療剤
|
TW200800951A
(en)
*
|
2005-08-09 |
2008-01-01 |
Novartis Ag |
Substituted imidazole compounds as KSP inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US8273747B2
(en)
|
2006-11-02 |
2012-09-25 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
GEP20125389B
(en)
|
2006-11-13 |
2012-01-25 |
Novartis Ag |
Substituted pyrazole and triazole compounds as ksp inhibitors
|
WO2008086122A2
(en)
|
2007-01-05 |
2008-07-17 |
Novartis Ag |
Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
US8822497B2
(en)
|
2007-03-01 |
2014-09-02 |
Novartis Ag |
PIM kinase inhibitors and methods of their use
|
US8293769B2
(en)
|
2007-05-21 |
2012-10-23 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
MX2009013815A
(es)
|
2007-06-22 |
2010-03-01 |
Arqule Inc |
Compuestos de quinazolinona y metodos de uso para los mismos.
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
CA3092449A1
(en)
|
2008-11-13 |
2010-05-20 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
EP2601293B1
(de)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
AU2013203620B2
(en)
|
2012-03-05 |
2015-11-19 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
PT2941426T
(pt)
|
2012-12-21 |
2018-07-18 |
Gilead Calistoga Llc |
Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
|
JP6207100B2
(ja)
|
2012-12-21 |
2017-10-04 |
ギリアード カリストガ エルエルシー |
イソキノリノンまたはキナゾリノンホスファチジルイノシトール3−キナーゼ阻害剤
|
PL3008053T3
(pl)
|
2013-06-14 |
2018-08-31 |
Gilead Calistoga Llc |
Inhibitory 3-kinazy fosfatydyloinozytolu
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
PL3083630T3
(pl)
|
2013-12-20 |
2020-02-28 |
Gilead Calistoga Llc |
Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
|
JP2017500319A
(ja)
|
2013-12-20 |
2017-01-05 |
ギリアード カリストガ エルエルシー |
(s)−2−(1−(9h−プリン−6−イルアミノ)プロピル)−5−フルオロ−3−フェニルキナゾリン−4(3h)−オンの塩酸塩の多形形態
|
EP3154958B1
(de)
|
2014-06-13 |
2020-10-07 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitoren
|
NZ726360A
(en)
*
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
JP6383810B2
(ja)
|
2014-06-13 |
2018-08-29 |
ギリアード サイエンシーズ, インコーポレイテッド |
ホスファチジルイノシトール3−キナーゼ阻害剤としてのキナゾリノン誘導体
|
BR112016028819A2
(pt)
|
2014-06-13 |
2017-08-22 |
Gilead Sciences Inc |
composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2017003723A1
(en)
|
2015-07-01 |
2017-01-05 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
WO2019023278A1
(en)
|
2017-07-25 |
2019-01-31 |
Crinetics Pharmaceuticals, Inc. |
MODULATORS OF SOMATOSTATIN AND USES THEREOF
|
CN111189935A
(zh)
*
|
2019-12-30 |
2020-05-22 |
卓和药业集团有限公司 |
盐酸右美托咪定的高效液相色谱分析方法
|